Artelo Biosciences Inc Stock Price, News & Analysis

Artelo Biosciences (ARTL) presented new data on ART26.12, their lead clinical Fatty Acid Binding Protein 5 (FABP5) inhibitor, for osteoarthritis (OA) pain treatment. In preclinical studies at Stony Brook University, ART26.12 showed superior symptom relief compared to naproxen in a surgical rodent OA model, demonstrating significant improvement in weight-bearing across all tested doses. The compound exhibited a clear dose-response relationship, with higher concentrations providing better pain relief.

The FDA has cleared ART26.12 for its first-in-human Phase 1 single ascending dose study, with initial results expected in H1 2025. The treatment targets over 500 million people globally affected by OA, according to WHO, and represents a potential alternative to NSAIDs and opioids.

Artelo Biosciences (NASDAQ: ARTL) reported Q3 2024 financial results and provided updates on its clinical pipeline. The company ended the quarter with $4.9 million in cash and investments. Net loss was $1.1 million ($0.35 per share), compared to $2.4 million in Q3 2023. R&D expenses decreased to $0.3 million from $1.6 million year-over-year. The company received $1.3 million in R&D tax credits from the UK government.

Multiple clinical readouts are expected over the next 15 months. The Phase 2 CAReS trial for ART27.13 in cancer-related anorexia is expected to complete enrollment in early 2025. FDA clearance was received for ART26.12 trials in chemotherapy-induced peripheral neuropathy, with Phase 1 results expected in H1 2025. ART12.11 clinical trials for anxiety and depression are planned for 2025.

Artelo Biosciences (Nasdaq: ARTL) announced that its lead clinical FABP inhibitor, ART26.12, has been accepted into the NIH's Preclinical Screening Platform for Pain (PSPP) program, part of the HEAL Initiative. The PSPP program evaluates non-opioid assets in preclinical pain models and is open to researchers globally. The HEAL Initiative aims to address the overdose epidemic and pain crisis by improving prevention, treatment strategies, and pain management. Artelo previously received FDA clearance for first-in-human studies of ART26.12, with initial results expected in the first half of 2025.

Artelo Biosciences, a clinical-stage pharmaceutical company focusing on lipid-signaling pathways for various medical conditions, announced its participation in the Maxim Group 2024 Virtual Healthcare Summit. The event is scheduled for October 15-17, 2024.

CEO Gregory D. Gorgas will engage in a fireside chat with Jason McCarthy, Maxim's Senior MD and Head of Biotechnology Research analyst, on Wednesday, October 16, 2024, at 4:00 p.m. ET. Interested parties can access the webcast by registering at the provided link.

Artelo Biosciences (Nasdaq: ARTL) focuses on developing treatments for people living with cancer, pain, dermatologic and neurological conditions. This participation offers an opportunity for investors and interested parties to gain insights into the company's progress and future plans.

Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York City. CEO Gregory D. Gorgas will represent the company, with an on-demand presentation available to registered attendees starting September 9 at 7:00 AM Eastern Time.

The presentation will be accessible via webcast on the conference platform and Artelo's investor relations website. Management will also engage in one-on-one meetings with qualified investors throughout the conference. Artelo focuses on modulating lipid-signaling pathways to develop treatments for cancer, pain, and dermatologic and neurological conditions.

Artelo Biosciences (Nasdaq: ARTL) reported its Q2 2024 financial results and provided a business update. The company is entering a productive phase in clinical development, with multiple readouts expected over the next 18 months. Key highlights include:

- FDA clearance to initiate clinical trials for ART26.12 for chemotherapy-induced peripheral neuropathy
- Anticipated full enrollment in Phase 2a of the CAReS trial for ART27.13 by early 2025
- ART12.11 in final stages of product formulation, potential clinical study entry in early 2025

Financially, Artelo reported $5.6 million in cash and cash equivalents as of June 30, 2024, with an additional $1.3 million received from UK R&D tax credits in July. Q2 2024 net loss was $2.4 million, or $0.75 per share, compared to $1.6 million, or $0.56 per share, in Q2 2023.

Artelo Biosciences (Nasdaq: ARTL) has received FDA clearance for its Investigational New Drug (IND) application for ART26.12, a selective Fatty Acid Binding Protein 5 (FABP5) inhibitor. This clearance allows Artelo to initiate a Phase 1 single ascending dose study for chemotherapy-induced peripheral neuropathy (CIPN), a condition with no FDA-approved treatment. ART26.12 is being developed as a non-opioid approach to manage painful neuropathies. The company expects Phase 1 trial results in the first half of 2025. Artelo's FABP inhibitor platform has attracted interest from potential partners due to its preclinical efficacy, novel mechanism, and strong patent estate.

Artelo Biosciences presented comparative preclinical data on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium. Findings revealed ART12.11, a novel cannabidiol: tetramethylpyrazine cocrystal, has a unique pharmacokinetic profile, potentially superior to existing treatments for anxiety-related disorders. Research showed ART12.11 increased plasma levels of CBD in rodents and displayed efficacy in reducing anxiety and depressive symptoms. The drug demonstrated similar plasma levels of CBD as Epidiolex, suggesting its potential as an effective treatment. Artelo is currently optimizing ART12.11's oral delivery formulation.

Artelo Biosciences (Nasdaq: ARTL) announced promising data from several research studies on its Fatty Acid Binding Protein 5 (FABP5) inhibitors at the ICRS Symposium, held June 30 – July 5, 2024, in Salamanca, Spain. The studies demonstrated the potential of FABP5 inhibitors in treating cancer, psoriasis, and anxiety disorders. ART26.12, one of Artelo’s lead inhibitors, showed anti-tumor effects in colon cancer models and potential for treating chemotherapy-induced peripheral neuropathy and psoriasis. Another inhibitor, SBFI103, improved depressive-like behaviors in preclinical studies. These findings support further development of FABP5 inhibitors, with first-in-human trials expected next year.